# Ennovabio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ennovabio

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.ennovabio.com
- Total disclosed funding: $14M
- Latest round: Series B (Oct 13, 2025)
- Investors on record: 8

## About

Founded in 2016 and based in Shanghai, China, Ennovabio operates as a drug research and development company that focuses on antitumor field. 50% of the company's employees have a doctoral degree and 80% members have master's degree. Dr. Jianglei, the founder and CEO of the company, is the CEO of HaiHe Biopharma Co., Ltd. In October 2025, Ennovabio raised a series B++ funding from new investor Pudong Venture Capital, returning investor Shanghai Kangcheng Investment Management.
The company provides new anti-tumor drugs and treatment methods for patients. The company develops anti-tumor new drug development platform that bases on combination targeting strategy. The company focuses on tumors, autoimmune diseases and inflammatory diseases field. The core technology of the company includes medicinal chemistry, bioinformatics and statistics.
The company will accelerate its R&D pipeline and provide more breakthrough solutions for the treatment of complex diseases.

## Funding rounds

- Series B, Oct 13, 2025 — Shanghai Kangcheng Investment Management, Pudong Venture Capital
- Series B, Sep 26, 2021 — Sunland Capital, Shanghai Zhangke Lingyi Investment Management Co., LTD, Tiliang Capital, Huasai Zhikang
- Series A, Nov 28, 2019, $14M — HighLight Capital, MPC

## Investors

- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A
- MPC — Series A
- Sunland Capital — Series B
- Shanghai Zhangke Lingyi Investment Management Co., LTD — Series B
- Tiliang Capital — Series B
- Huasai Zhikang — Series B
- Shanghai Kangcheng Investment Management — Series B
- Pudong Venture Capital (https://capitalatlas.ai/funds/pudong-venture-capital) — Series B